logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Core subscription business continues to push forward! DocuSign (DOCU.US) Q3 revenue and profit exceed expectations, raise full-year performance guidance.

date
05/12/2025
According to the financial news app, due to the growth in subscription revenue, electronic signature solution provider DocuSign(DOCU.US) has released better-than-expected third quarter financial report, while also raising its full-year performance guidance.
Latest
3 m ago
On the morning of December 5th, Meituan officially announced that starting today, the "Meituan" app will be fully updated to a new version called "Taobao Flash Sale".
3 m ago
CITIC Securities: Asian stock markets need to focus more on the structural allocation opportunities brought about by changes in fundamental clues.
4 m ago
Spot gold breaks through $4210 per ounce, up 0.03% intraday.
4 m ago
Jin Fang Medicine-B (02595): The registration clinical trial of GFH375 for the treatment of metastatic pancreatic cancer has been initiated at the first research center. This is the world's first phase III study of an oral KRAS G12D inhibitor as monotherapy compared to chemotherapy.
5 m ago
SoftBank Group's stock price increased by 3.7%.
See all latestmore
logo
Contact US
qr
+852 - 60190728
[email protected]
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.